Tech Company Financing Transactions
Locus Biosciences Funding Round
On 11/15/2017, Locus Biosciences raised $19 million in Series A funding from ARTIS Ventures, Abstract Ventures and North Carolina Biotechnology Center.
Transaction Overview
Company Name
Announced On
11/15/2017
Transaction Type
Venture Equity
Venture Equity
Venture Equity
Amount
$19,000,000
Round
Series A
Investors
ARTIS Ventures (Lead Investor) (Stuart Peterson)
Proceeds Purpose
The Series A financing will fund the company through filing its first IND, as well as the subsequent first-in-human trial.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
523 Davis Dr. 350
Morrisville, NC 27560
USA
Morrisville, NC 27560
USA
Phone
Website
Email Address
Overview
Locus Biosciences is an emerging biotechnology company focused on the discovery and development of a next generation CRISPR-Cas platform for precision antimicrobials. Our novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Garofolo
Chief Scientific Officer
David Ousterout
VP - Bus. Development
Paul Kim
VP - Bus. Development
Joseph Nixon
VP - Operations
Jamie Kime
Browse more venture capital transactions:
Prev: 11/15/2017: Torque venture capital transaction
Next: 11/15/2017: Lessonly venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs